BETOPTIC Drug Patent Profile

Which patents cover Betoptic, and when can generic versions of Betoptic launch?

Betoptic is a drug marketed by Sandoz, Alcon, and Novartis. and is included in three NDAs.

The generic ingredient in BETOPTIC is betaxolol hydrochloride; pilocarpine hydrochloride. There are eleven drug master file entries for this compound. Additional details are available on the betaxolol hydrochloride; pilocarpine hydrochloride profile page.

Summary for BETOPTIC

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for BETOPTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	BETOPTIC	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019270-001	Aug 30, 1985	AT	RX	Yes	Yes
Alcon	BETOPTIC PILO	betaxolol hydrochloride; pilocarpine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020619-001	Apr 17, 1997		DISCN	No	No
Novartis	BETOPTIC S	betaxolol hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	019845-001	Dec 29, 1989		RX	Yes	Yes

International Patents for BETOPTIC

See the table below for patents covering BETOPTIC around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	214303	UN PROCEDIMIENTO PARA PREPARAR NUEVOS DERIVADOS DE(CICLOALQUILALQUILOXI-(O TIO,O-SULFONIL-ALQUIL)-(O ALQUILOXI FENOXI)-1AMINO-3-PROPANOL-2
Austria	344683
Austria	A812076
Australia	1925976
Australia	501581

Last updated: February 9, 2026

What is Betoptic and its Market Position?

Betoptic (betaxolol hydrochloride) is a beta-blocker ophthalmic solution approved for treating open-angle glaucoma and ocular hypertension. Its primary function is lowering intraocular pressure (IOP). The drug has been on the market since 1987, with global sales dominated by established pharmaceutical companies, notably Alcon (a Novartis division), which holds the majority share.

Its sales are driven by a stable patient base, periodic renewal, and the slow-shifting preference toward preservative-free formulations. Betoptic's brand recognition and clinical efficacy have kept it relevant amid newer medications, but intense generic competition limits potential for high-margin growth.

What Are the Key Market Fundamentals?

Aspect	Data/Details
Market Size	The global glaucoma drugs market was valued at approximately US$5.8 billion in 2022.
Growth Rate	Expected CAGR of 4.9% from 2023 to 2030 (Grand View Research).
Major Players	Novartis (Alcon), Allergan (AbbVie), Bausch + Lomb, Merck, and generic manufacturers.
Patent Status	Betoptic's patent protection expired decades ago; current formulations are off-patent, leading to widespread generics.
Pricing	Topical ocular drugs are generics, with low per-unit costs, generally $10-$30 per bottle.

How Does Betoptic Compare to Alternatives?

Parameter	Betoptic	Alternatives
Mechanism	Beta-1 selective blocker	Non-selective beta-blockers like timolol, brimonidine, prostaglandin analogs
Efficacy	Reduces IOP by 20–25%	Similar efficacy, but some drugs yield higher IOP reduction (e.g., latanoprost 30%)
Side Effects	Fewer systemic side effects compared to non-selective beta-blockers	Increased risk of systemic hypotension, bronchospasm with non-selectives
Patient Tolerance	Well tolerated; few known allergy issues	Variation exists; some drugs cause eye pigmentation or eyelash growth

What Are the Investment and R&D Trends?

Leaders in the glaucoma space increasingly focus on drug delivery innovations such as sustained-release devices. R&D is examining:

• New molecular entities targeting different pathways (e.g., Rho kinase inhibitors).
• Combination therapies that simplify regimens.
• Delivery systems like ocular inserts or implants.

For Betoptic, the off-patent status constrains direct innovation investments. Instead, companies leverage reformulations or combination drugs to extend life cycle.

Major biotech firms are less inclined to invest heavily in Betoptic's market segment due to limited margins and high competition. Instead, focus shifts toward novel compounds or delivery methods.

What Are Regulatory and Pricing Dynamics?

Regulatory pathways are straightforward for established drugs like Betoptic, relying on generic approvals. The Low-cost nature of generics compresses reimbursement margins.

Pricing policies in developed markets favor cost containment, with some health systems negotiating significant discounts for generics. This environment exerts downward pressure on sales revenue, especially as patents expire and generic penetration increases.

In emerging markets, less competition and growing glaucoma prevalence sustain volume sales but often at lower prices.

What Is the Future Outlook for Betoptic?

• Market Penetration: Limited growth due to generic competition and market saturation.
• Lifecycle Management: Focus on new formulations, fixed-dose combinations, and delivery devices.
• Regulatory Strategy: Likely limited, as the drug's off-patent status restricts exclusivity.
• Investment Perspective: Minimal direct R&D investment; focus on adjacent innovative therapies holds more potential.

Key Takeaways

• Betoptic is a long-established, generic ophthalmic drug with stable, but modest, revenue streams.
• The global glaucoma therapy market is growing steadily, with innovation primarily in delivery systems and novel molecule classes.
• Off-patent status limits direct R&D and expansion opportunities for Betoptic.
• Competitive pricing pressures constrain profitability, emphasizing the importance of lifecycle strategies.
• Future growth hinges on reformulations, combination therapies, or device innovations rather than the original molecule.

FAQs

1. Is Betoptic still profitable for pharmaceutical companies?
Profitability is limited due to generic competition and low pricing. Companies may find more value in lifecycle extension through formulations than the original molecule.

2. Are there significant patent barriers for Betoptic?
No. The original patents have expired since the late 20th century, leading to widespread generics.

3. What are the main competitors to Betoptic?
Non-selective beta-blockers like timolol, prostaglandin analogs such as latanoprost, and combination therapies.

4. Can Betoptic be used in combination with other glaucoma drugs?
Yes. Combination therapy is common, but formulations are marketed separately, often as fixed-dose combinations with other agents.

5. What innovations could reinvigorate Betoptic’s market?
Development of sustained-release implants or combination formulations might provide new growth avenues.

---

Citations

[1] Grand View Research. Glaucoma Drugs Market Size, Share & Trends Analysis Report. 2022.